Shorter h. pylori treatment may work just as well as longer one

NCT ID NCT07333001

Completed Disease control Sponsor: Yueyue Li Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at 508 adults with H. pylori infection to see if a 7-day triple therapy (vonoprazan, amoxicillin, tetracycline) works as well as a 14-day dual therapy (vonoprazan, amoxicillin). The goal was to compare how often the infection is cleared and how many side effects occur. The study used past medical records from a hospital in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vonoprazan, amoxicillin, and tetracycline
What this could lead to: If successful, a shorter 7-day treatment could be as effective as the standard 14-day regimen, making it more convenient for patients.
What could go wrong: This is a retrospective study, not a randomized trial, so results may be less reliable. The shorter regimen may not work as well in people with antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTIONS

Contacts and locations

Locations

Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.